<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00113802</url>
  </required_header>
  <id_info>
    <org_study_id>IM-T-hLL2-18-US</org_study_id>
    <nct_id>NCT00113802</nct_id>
  </id_info>
  <brief_title>Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia</brief_title>
  <official_title>A Phase II, Single-Arm Trial of Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients With Waldenstrom's Macroglobulinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether epratuzumab provides effective therapy in&#xD;
      Waldenström's Macroglobulinemia (WM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, single-arm study of epratuzumab is in patients with Waldenström's&#xD;
      Macroglobulinemia (WM) who failed chemotherapy. After baseline evaluations, patients receive&#xD;
      epratuzumab infused over approximately 30-60 minutes at 360 mg/m2, administered once weekly&#xD;
      for 4 consecutive weeks (days 1, 8, 15, 22). Post-treatment evaluations occur on the day of&#xD;
      the last infusion, then at 6 and 12 weeks. Patients without progression of disease continue&#xD;
      long-term follow up until disease progression or for at least 5 years, with evaluations every&#xD;
      3 months for 2 years, then semi-annually. Otherwise, follow-up is only required until&#xD;
      resolution of any treatment related abnormalities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum measurements of IgM will be the primary determination of efficacy.</measure>
  </primary_outcome>
  <enrollment>31</enrollment>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epratuzumab (hLL2- anti-CD22 humanized antibody)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of Waldenström's Macroglobulinemia using criteria proposed at 2nd&#xD;
             International Workshop on WM, Athens, Greece, 2002.&#xD;
&#xD;
          -  Measurable disease, defined as serum monoclonal IgM protein ≥1000 mg/dL by&#xD;
             electrophoresis.&#xD;
&#xD;
          -  Lymphoplasmacytic infiltration of the bone marrow &gt;10% involvement.&#xD;
&#xD;
          -  Failed at least one, but no more than 3, regimen(s) of prior therapy.&#xD;
&#xD;
        (Please consult with study site for full eligibility criteria)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Weill Medical College of Cornell/ New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Physicans &amp; Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <study_first_submitted>June 10, 2005</study_first_submitted>
  <study_first_submitted_qc>June 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2005</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <keyword>Epratuzumab (hLL2- anti-CD22 humanized antibody)</keyword>
  <keyword>Waldenstrom's Macroglobulinemia</keyword>
  <keyword>Waldenstrom Macroglobulinemia</keyword>
  <keyword>Hematologic Disease</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Paraproteinemias</keyword>
  <keyword>Vascular Hemostatic Disorders</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epratuzumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

